目的观察注射用乌司他丁联合地塞米松磷酸钠注射液治疗急性呼吸窘迫综合征的临床效果。方法选取2016年3月—2017年3月成都市第二人民医院收治的急性呼吸窘迫综合征患者96例为研究的对象,将所有患者随机分为对照组和治疗组,每组各48例。...目的观察注射用乌司他丁联合地塞米松磷酸钠注射液治疗急性呼吸窘迫综合征的临床效果。方法选取2016年3月—2017年3月成都市第二人民医院收治的急性呼吸窘迫综合征患者96例为研究的对象,将所有患者随机分为对照组和治疗组,每组各48例。对照组静脉滴注地塞米松磷酸钠注射液,5 mg加入到5%葡萄糖注射液250 m L中,2次/d。治疗组在对照组的基础上静脉滴注注射用乌司他丁,5万单位加入到5%葡萄糖注射液250 m L中,2次/d。两组患者均连续治疗2周。观察两组的临床疗效,比较两组的住院时间、住重症监护室(ICU)时间、病死率和肺功能指标。结果治疗后,对照组和治疗组的总有效率分别为77.1%、95.8%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组住院时间、住ICU时间、病死率均低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组氧合指数均显著升高,治疗组呼吸频率显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论注射用乌司他丁联合地塞米松磷酸钠注射液治疗急性呼吸窘迫综合征具有较好的临床疗效,可以改善肺功能,缩短住院时间和住ICU时间,降低病死率,具有一定的临床推广应用价值。展开更多
Background and aims:Patients in the intensive care unit(ICU)with acute pancreatitis(AP)are at risk for extra-pancreatic complications given their severe illness and prolonged length of stay.We sought to determine the ...Background and aims:Patients in the intensive care unit(ICU)with acute pancreatitis(AP)are at risk for extra-pancreatic complications given their severe illness and prolonged length of stay.We sought to determine the rate of extra-pancreatic complications and its effect on length of stay(LOS)and mortality in ICU patients with AP.Methods:We performed a retrospective cohort study of ICU patients admitted to a tertiary-care center with a diagnosis of AP.A total of 287 ICU patients had a discharge diagnosis of AP,of which 163 met inclusion criteria.We calculated incidence rates of extra-pancreatic complications and performed a univariate and multi-variable analysis to determine predictors of LOS and mortality.Results:There were a total of 158 extra-pancreatic complications(0.97 extra-pancreatic complications per patient).Ninetyfive patients had at least one extra-pancreatic complication,whereas 68 patients had no extra-pancreatic complications.Patients with extra-pancreatic complications had a significantly longer LOS(14.7 vs 8.8 days,p<0.01)when controlling for local pancreatic complications.Patients with non-infectious extra-pancreatic complications had a higher rate of mortality(24.0%vs 16.2%,p=0.04).Patients requiring dialysis was an independent predictor for LOS and mortality(incidence risk ratio[IRR]1.73,95%confidence interval[CI]:1.263–2.378 and IRR 1.50,95%CI 1.623–6.843,p<0.01)on multi-variable analysis.Coronary events were also a predictor for mortality(p=0.05).Other extra-pancreatic complications were not significant.Conclusions:Extra-pancreatic complications occur frequently in ICU patients with AP and impact LOS.Patients with noninfectious extra-pancreatic complications have a higher mortality rate.After controlling for local pancreatic complications,patients requiring dialysis remained an independent predictor for LOS and mortality.展开更多
文摘目的观察注射用乌司他丁联合地塞米松磷酸钠注射液治疗急性呼吸窘迫综合征的临床效果。方法选取2016年3月—2017年3月成都市第二人民医院收治的急性呼吸窘迫综合征患者96例为研究的对象,将所有患者随机分为对照组和治疗组,每组各48例。对照组静脉滴注地塞米松磷酸钠注射液,5 mg加入到5%葡萄糖注射液250 m L中,2次/d。治疗组在对照组的基础上静脉滴注注射用乌司他丁,5万单位加入到5%葡萄糖注射液250 m L中,2次/d。两组患者均连续治疗2周。观察两组的临床疗效,比较两组的住院时间、住重症监护室(ICU)时间、病死率和肺功能指标。结果治疗后,对照组和治疗组的总有效率分别为77.1%、95.8%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组住院时间、住ICU时间、病死率均低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组氧合指数均显著升高,治疗组呼吸频率显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论注射用乌司他丁联合地塞米松磷酸钠注射液治疗急性呼吸窘迫综合征具有较好的临床疗效,可以改善肺功能,缩短住院时间和住ICU时间,降低病死率,具有一定的临床推广应用价值。
文摘Background and aims:Patients in the intensive care unit(ICU)with acute pancreatitis(AP)are at risk for extra-pancreatic complications given their severe illness and prolonged length of stay.We sought to determine the rate of extra-pancreatic complications and its effect on length of stay(LOS)and mortality in ICU patients with AP.Methods:We performed a retrospective cohort study of ICU patients admitted to a tertiary-care center with a diagnosis of AP.A total of 287 ICU patients had a discharge diagnosis of AP,of which 163 met inclusion criteria.We calculated incidence rates of extra-pancreatic complications and performed a univariate and multi-variable analysis to determine predictors of LOS and mortality.Results:There were a total of 158 extra-pancreatic complications(0.97 extra-pancreatic complications per patient).Ninetyfive patients had at least one extra-pancreatic complication,whereas 68 patients had no extra-pancreatic complications.Patients with extra-pancreatic complications had a significantly longer LOS(14.7 vs 8.8 days,p<0.01)when controlling for local pancreatic complications.Patients with non-infectious extra-pancreatic complications had a higher rate of mortality(24.0%vs 16.2%,p=0.04).Patients requiring dialysis was an independent predictor for LOS and mortality(incidence risk ratio[IRR]1.73,95%confidence interval[CI]:1.263–2.378 and IRR 1.50,95%CI 1.623–6.843,p<0.01)on multi-variable analysis.Coronary events were also a predictor for mortality(p=0.05).Other extra-pancreatic complications were not significant.Conclusions:Extra-pancreatic complications occur frequently in ICU patients with AP and impact LOS.Patients with noninfectious extra-pancreatic complications have a higher mortality rate.After controlling for local pancreatic complications,patients requiring dialysis remained an independent predictor for LOS and mortality.
